• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

信：COVID-19 结局和抗 TNF 治疗——全面的证据很重要。

Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters.

机构信息

Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan.

Department of Internal Medicine, Chung-Shan Medical University Hospital, Taichung, Taiwan.

出版信息

Aliment Pharmacol Ther. 2022 May;55(9):1233-1234. doi: 10.1111/apt.16872.

DOI:10.1111/apt.16872
PMID:35429022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9111426/
Abstract

This article is linked to Kokkotis et al papers. To view these articles, visit https://doi.org/10.1111/apt.16717 and https://doi.org/10.1111/apt.16904

摘要

本文与 Kokkotis 等人的论文相关。欲查看这些文章，请访问 https://doi.org/10.1111/apt.16717 和 https://doi.org/10.1111/apt.16904。

相似文献

1
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters.信：COVID-19 结局和抗 TNF 治疗——全面的证据很重要。
Aliment Pharmacol Ther. 2022 May;55(9):1233-1234. doi: 10.1111/apt.16872.
2
Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe?2019冠状病毒病大流行期间的抗TNF治疗：是福是祸？
J Crohns Colitis. 2022 May 10;16(4):517-518. doi: 10.1093/ecco-jcc/jjab167.
3
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19.抗 TNF 药物的再利用潜力——治疗 COVID-19 的新策略。
Med. 2020 Dec 18;1(1):90-102. doi: 10.1016/j.medj.2020.11.005. Epub 2020 Dec 3.
4
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.信件：2019冠状病毒病的结局与抗TNF治疗——全面的证据很重要。作者回复。
Aliment Pharmacol Ther. 2022 May;55(9):1235-1236. doi: 10.1111/apt.16904.
5
Role of tumor necrosis factor-α in the mortality of hospitalized patients with severe and critical COVID-19 pneumonia.肿瘤坏死因子-α在住院的重症和危重症 COVID-19 肺炎患者死亡率中的作用。
Aging (Albany NY). 2021 Nov 1;13(21):23895-23912. doi: 10.18632/aging.203663.
6
Use of Tumor Necrosis Factor Inhibitors During the COVID-19 Pandemic-Evidence in Favor of Monotherapy.2019冠状病毒病大流行期间肿瘤坏死因子抑制剂的使用——支持单药治疗的证据
JAMA Netw Open. 2021 Oct 1;4(10):e2129707. doi: 10.1001/jamanetworkopen.2021.29707.
7
Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments.系统评价与荟萃分析：接受抗 TNF 治疗的患者的 COVID-19 结局。
Aliment Pharmacol Ther. 2022 Jan;55(2):154-167. doi: 10.1111/apt.16717. Epub 2021 Dec 8.
8
Tumor necrosis factor inhibitors and methotrexate are associated with decreased COVID-19-related hospitalization: Follow up of "Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors and methotrexate".肿瘤坏死因子抑制剂和甲氨蝶呤与COVID-19相关住院率降低有关：“服用肿瘤坏死因子抑制剂和甲氨蝶呤的COVID-19患者的临床结局”随访
J Am Acad Dermatol. 2023 Jun;88(6):1385-1386. doi: 10.1016/j.jaad.2023.02.002. Epub 2023 Feb 10.
9
Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'.关于“使用肿瘤坏死因子-α抑制剂依那西普治疗的脊柱关节炎患者从新冠病毒感染中康复。一例接受乌司奴单抗治疗的银屑病关节炎合并新冠病毒感染患者的报告”的通信
Ann Rheum Dis. 2021 May;80(5):e79. doi: 10.1136/annrheumdis-2020-218029. Epub 2020 Aug 18.
10
[Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].新型冠状病毒肺炎感染后的生物治疗：在生物治疗下，严重急性呼吸综合征冠状病毒2抗体阳性状态的新型冠状病毒肺炎感染无再激活情况
Z Rheumatol. 2020 Aug;79(6):574-577. doi: 10.1007/s00393-020-00824-0.

引用本文的文献

1
Tumour necrosis factor-alpha inhibitors decrease mortality in COVID-19: a systematic review and meta-analysis.肿瘤坏死因子-α抑制剂可降低COVID-19的死亡率：一项系统评价和荟萃分析。
Crit Care. 2025 Jun 6;29(1):232. doi: 10.1186/s13054-025-05420-9.
2
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.信件：2019冠状病毒病的结局与抗TNF治疗——全面的证据很重要。作者回复。
Aliment Pharmacol Ther. 2022 May;55(9):1235-1236. doi: 10.1111/apt.16904.

本文引用的文献

1
Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments.系统评价与荟萃分析：接受抗 TNF 治疗的患者的 COVID-19 结局。
Aliment Pharmacol Ther. 2022 Jan;55(2):154-167. doi: 10.1111/apt.16717. Epub 2021 Dec 8.
2
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明：系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
3
The Coronavirus Disease 2019 Pandemic's Effect on Critical Care Resources and Health-Care Providers: A Global Survey.2019 年冠状病毒病大流行对重症监护资源和医疗保健提供者的影响：全球调查。
Chest. 2021 Feb;159(2):619-633. doi: 10.1016/j.chest.2020.09.070. Epub 2020 Sep 11.
4
Bias in meta-analysis detected by a simple, graphical test.通过一种简单的图形检验检测荟萃分析中的偏倚。
BMJ. 1997 Sep 13;315(7109):629-34. doi: 10.1136/bmj.315.7109.629.
5
Operating characteristics of a rank correlation test for publication bias.用于发表偏倚的秩相关检验的操作特征
Biometrics. 1994 Dec;50(4):1088-101.